Danaher Non-GAAP EPS of $2.23 beats by $0.04, revenue of $6.84B beats by $30M

Forecasted Core Sales Growth (Decline) by Segment and Adjusted Diluted Net Earnings Per Common Share.

	% Change Three-Month Period Ending March 27, 2026 vs. Comparable 2025 Period	% Change Year Ending December 31, 2026 vs. Comparable 2025 Period
Biotechnology	+High-single digit	~+6.0%
Life Sciences	Flat/ -Low-single digit	Flat
Diagnostics	-Low-single digit	+Low-single digit
Total Company core sales growth (non-GAAP)	+Low-single digit	+3.0% – +6.0%

		Year Ending December 31, 2026
Adjusted diluted net earnings per common share (non-GAAP)		$8.35 – $8.50